1	Recurrence	Recurrence	B-NP	NN	O	14	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	Helicobacter	Helicobacter	B-NP	NN	O	5	NMOD
4	pylori	pylori	I-NP	NN	O	5	NMOD
5	infection	infection	I-NP	NN	O	7	NMOD
6	1	1	I-NP	CD	O	7	NMOD
7	year	year	I-NP	NN	O	2	PMOD
8	after	after	B-PP	IN	O	1	NMOD
9	successful	successful	B-NP	JJ	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	:	:	O	:	O	1	P
12	prospective	prospective	B-NP	JJ	O	14	NMOD
13	cohort	cohort	I-NP	JJ	O	14	NMOD
14	study	study	I-NP	NN	O	0	ROOT
15	in	in	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	Republic	Republic	I-NP	NNP	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	Yemen	Yemen	B-NP	NNP	O	18	PMOD
20	.	.	O	.	O	14	P

1	To	To	B-VP	TO	O	2	VMOD
2	investigate	investigate	I-VP	VB	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	prevalence	prevalence	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	Helicobacter	Helicobacter	B-NP	NN	O	8	NMOD
7	pylori	pylori	I-NP	NN	O	8	NMOD
8	infection	infection	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	4	NMOD
10	dyspeptic	dyspeptic	B-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	Republic	Republic	I-NP	NNP	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	Yemen	Yemen	B-NP	NNP	O	22	NMOD
17	and	and	O	CC	O	22	NMOD
18	the	the	B-NP	DT	O	22	NMOD
19	recurrence	recurrence	I-NP	NN	O	22	NMOD
20	rate	rate	I-NP	NN	O	22	NMOD
21	1	1	I-NP	CD	O	22	NMOD
22	year	year	I-NP	NN	O	15	PMOD
23	after	after	B-PP	IN	O	4	NMOD
24	apparently	apparently	B-NP	RB	O	25	AMOD
25	successful	successful	I-NP	JJ	O	26	NMOD
26	eradication	eradication	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	total	total	I-NP	NN	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	275	275	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	chronic	chronic	B-NP	JJ	O	8	NMOD
8	dyspepsia	dyspepsia	I-NP	NN	O	6	PMOD
9	seen	see	B-VP	VBN	O	8	NMOD
10	in	in	B-PP	IN	O	9	VMOD
11	one	one	B-NP	CD	O	12	NMOD
12	clinic	clinic	I-NP	NN	O	10	PMOD
13	were	be	B-VP	VBD	O	0	ROOT
14	enrolled	enrol	I-VP	VBN	O	13	VC
15	.	.	O	.	O	13	P

1	Gastric	Gastric	B-NP	JJ	O	2	NMOD
2	biopsies	biopsy	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	obtained	obtain	I-VP	VBN	O	3	VC
5	at	at	B-PP	IN	O	4	VMOD
6	endoscopy	endoscopy	B-NP	NN	O	10	NMOD
7	and	and	I-NP	CC	O	10	NMOD
8	H.	H.	I-NP	NN	O	10	NMOD
9	pylori	pylori	I-NP	NN	O	10	NMOD
10	infection	infection	I-NP	NN	O	5	PMOD
11	was	be	B-VP	VBD	O	3	VMOD
12	diagnosed	diagnose	I-VP	VBN	O	11	VC
13	using	use	B-VP	VBG	O	11	VMOD
14	the	the	B-NP	DT	O	17	NMOD
15	rapid	rapid	I-NP	JJ	O	17	NMOD
16	urease	urease	I-NP	NN	O	17	NMOD
17	test	test	I-NP	NN	O	13	OBJ
18	.	.	O	.	O	3	P

1	Patients	Patient	B-NP	NNS	O	6	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	H.	H.	B-NP	NN	O	5	NMOD
4	pylori	pylori	I-NP	NN	O	5	NMOD
5	infection	infection	I-NP	NN	O	2	PMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	given	give	I-VP	VBN	O	6	VC
8	either	either	O	CC	O	13	NMOD
9	clarithromycin	clarithromycin	B-NP	NN	O	13	NMOD
10	or	or	O	CC	O	13	NMOD
11	metronidazole-based	metronidazole-based	B-NP	JJ	O	13	NMOD
12	triple	triple	I-NP	JJ	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	7	OBJ
14	.	.	O	.	O	6	P

1	Six	Six	B-NP	CD	O	2	NMOD
2	weeks	week	I-NP	NNS	O	6	NMOD
3	later	later	B-NP	RB	O	6	NMOD
4	H.	H.	I-NP	NN	O	6	NMOD
5	pylori	pylori	I-NP	NN	O	6	NMOD
6	status	status	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	assessed	assess	I-VP	VBN	O	7	VC
9	using	use	B-VP	VBG	O	8	VMOD
10	the	the	B-NP	DT	O	13	NMOD
11	C-urea	C-urea	I-NP	NN	O	13	NMOD
12	breath	breath	I-NP	NN	O	13	NMOD
13	test	test	I-NP	NN	O	9	OBJ
14	(	(	O	(	O	16	DEP
15	C-UBT	C-UBT	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	.	.	O	.	O	7	P

1	Those	Those	B-NP	DT	O	8	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	were	be	B-VP	VBD	O	2	SBAR
4	negative	negative	B-ADJP	JJ	O	3	PRD
5	for	for	B-PP	IN	O	4	AMOD
6	H.	H.	B-NP	NN	O	7	NMOD
7	pylori	pylori	I-NP	NN	O	5	PMOD
8	had	have	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	11	NMOD
10	further	further	I-NP	JJ	O	11	NMOD
11	C-UBT	C-UBT	I-NP	NN	O	8	OBJ
12	after	after	B-PP	IN	O	8	VMOD
13	1	1	B-NP	CD	O	14	NMOD
14	year	year	I-NP	NN	O	12	PMOD
15	to	to	B-VP	TO	O	16	VMOD
16	establish	establish	I-VP	VB	O	8	VMOD
17	the	the	B-NP	DT	O	19	NMOD
18	recurrence	recurrence	I-NP	NN	O	19	NMOD
19	rate	rate	I-NP	NN	O	16	OBJ
20	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	2	NMOD
2	prevalence	prevalence	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	H.	H.	B-NP	NN	O	6	NMOD
5	pylori	pylori	I-NP	NN	O	6	NMOD
6	infection	infection	I-NP	NN	O	3	PMOD
7	at	at	B-PP	IN	O	2	NMOD
8	entry	entry	B-NP	NN	O	7	PMOD
9	to	to	B-PP	TO	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	study	study	I-NP	NN	O	9	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	82.2	82.2	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	12	PRD
15	[	[	O	(	O	25	DEP
16	95	95	B-NP	CD	O	19	NMOD
17	%	%	I-NP	NN	O	19	NMOD
18	confidence	confidence	I-NP	NN	O	19	NMOD
19	interval	interval	I-NP	NN	O	24	NMOD
20	(	(	O	(	O	22	DEP
21	CI	CI	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	78-87	78-87	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	25	DEP
25	]	]	O	)	O	14	NMOD
26	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	4	NMOD
2	overall	overall	I-NP	JJ	O	4	NMOD
3	eradication	eradication	I-NP	NN	O	4	NMOD
4	rate	rate	I-NP	NN	O	6	SUB
5	6	6	B-NP	CD	O	4	NMOD
6	weeks	week	I-NP	NNS	O	9	SUB
7	after	after	B-SBAR	IN	O	6	NMOD
8	treatment	treatment	B-NP	NN	O	7	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	49.1	49.1	B-NP	CD	O	11	NMOD
11	%	%	I-NP	NN	O	9	PRD
12	(	(	O	(	O	18	DEP
13	95	95	B-NP	CD	O	17	NMOD
14	%	%	I-NP	NN	O	17	NMOD
15	CI	CI	I-NP	NN	O	17	NMOD
16	42.6-55.6	42.6-55.6	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	18	DEP
18	)	)	O	)	O	11	NMOD
19	by	by	B-PP	IN	O	9	VMOD
20	intention-to-treat	intention-to-treat	B-NP	JJ	O	21	NMOD
21	analysis	analysis	I-NP	NN	O	19	PMOD
22	,	,	O	,	O	9	VMOD
23	and	and	O	CC	O	25	NMOD
24	60	60	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	22	OBJ
26	(	(	O	(	O	32	DEP
27	95	95	B-NP	CD	O	31	NMOD
28	%	%	I-NP	NN	O	31	NMOD
29	CI	CI	I-NP	NN	O	31	NMOD
30	53-67	53-67	B-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	32	DEP
32	)	)	O	)	O	25	NMOD
33	by	by	B-PP	IN	O	25	NMOD
34	per-protocol	per-protocol	B-NP	JJ	O	35	NMOD
35	analysis	analysis	I-NP	NN	O	33	PMOD
36	.	.	O	.	O	9	P

1	Recurrence	Recurrence	B-NP	NN	O	2	NMOD
2	rate	rate	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	H.	H.	B-NP	NN	O	6	NMOD
5	pylori	pylori	I-NP	NN	O	6	NMOD
6	infection	infection	I-NP	NN	O	3	PMOD
7	at	at	B-PP	IN	O	2	NMOD
8	1	1	B-NP	CD	O	9	NMOD
9	year	year	I-NP	NN	O	7	PMOD
10	was	be	B-VP	VBD	O	26	VMOD
11	34	34	B-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	10	PRD
13	(	(	O	(	O	19	DEP
14	95	95	B-NP	CD	O	18	NMOD
15	%	%	I-NP	NN	O	18	NMOD
16	CI	CI	I-NP	NN	O	18	NMOD
17	14-45	14-45	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	19	DEP
19	)	)	O	)	O	12	NMOD
20	and	and	O	CC	O	26	VMOD
21	the	the	B-NP	DT	O	23	NMOD
22	only	only	I-NP	JJ	O	23	NMOD
23	predictor	predictor	I-NP	NN	O	26	SUB
24	of	of	B-PP	IN	O	23	NMOD
25	recurrence	recurrence	B-NP	NN	O	24	PMOD
26	was	be	B-VP	VBD	O	0	ROOT
27	an	an	B-NP	DT	O	31	NMOD
28	excess	excess	I-NP	JJ	O	31	NMOD
29	delta	delta	I-NP	NN	O	31	NMOD
30	C-UBT	C-UBT	I-NP	NN	O	31	NMOD
31	value	value	I-NP	NN	O	26	PRD
32	less	less	B-ADJP	JJR	O	38	AMOD
33	than	than	B-PP	IN	O	32	AMOD
34	3.5	3.5	B-NP	CD	O	33	PMOD
35	per	per	B-PP	IN	O	32	AMOD
36	million	million	B-NP	CD	O	35	PMOD
37	but	but	O	CC	O	38	AMOD
38	equal	equal	B-ADJP	JJ	O	41	AMOD
39	to	to	B-PP	TO	O	38	AMOD
40	or	or	O	CC	O	41	AMOD
41	greater	great	B-ADJP	JJR	O	31	NMOD
42	than	than	B-PP	IN	O	41	AMOD
43	2.5	2.5	B-NP	CD	O	42	PMOD
44	per	per	B-PP	IN	O	41	AMOD
45	million	million	B-NP	CD	O	44	PMOD
46	at	at	B-PP	IN	O	41	AMOD
47	6	6	B-NP	CD	O	48	NMOD
48	weeks	week	I-NP	NNS	O	46	PMOD
49	after	after	B-PP	IN	O	41	AMOD
50	treatment	treatment	B-NP	NN	O	49	PMOD
51	(	(	O	(	O	64	DEP
52	odds	odd	B-NP	NNS	O	53	NMOD
53	ratio	ratio	B-NP	NN	O	61	NMOD
54	2.28	2.28	I-NP	CD	O	53	NMOD
55	;	;	O	:	O	61	P
56	95	95	B-NP	CD	O	58	NMOD
57	%	%	I-NP	NN	O	58	NMOD
58	CI	CI	I-NP	NN	O	61	NMOD
59	1.17-4.44	1.17-4.44	I-NP	CD	O	58	NMOD
60	;	;	O	:	O	61	P
61	P	P	B-NP	NN	O	64	DEP
62	=	=	B-VP	SYM	O	61	NMOD
63	0.028	0.028	B-NP	CD	O	62	AMOD
64	)	)	O	)	O	31	NMOD
65	.	.	O	.	O	26	P

1	The	The	B-NP	DT	O	2	NMOD
2	prevalence	prevalence	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	H.	H.	B-NP	NN	O	6	NMOD
5	pylori	pylori	I-NP	NN	O	6	NMOD
6	infection	infection	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	dyspeptic	dyspeptic	B-NP	JJ	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	Yemen	Yemen	B-NP	NN	O	10	PMOD
12	is	be	B-VP	VBZ	O	23	VMOD
13	very	very	B-ADJP	RB	O	14	AMOD
14	high	high	I-ADJP	JJ	O	12	PRD
15	,	,	O	,	O	12	P
16	the	the	B-NP	DT	O	18	NMOD
17	eradication	eradication	I-NP	NN	O	18	NMOD
18	rate	rate	I-NP	NN	O	23	SUB
19	with	with	B-PP	IN	O	18	NMOD
20	standard	standard	B-NP	JJ	O	22	NMOD
21	triple	triple	I-NP	JJ	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	19	PMOD
23	was	be	B-VP	VBD	O	0	ROOT
24	unsatisfactory	unsatisfactory	B-ADJP	JJ	O	25	AMOD
25	probably	probably	B-ADVP	RB	O	23	VMOD
26	because	because	B-PP	IN	O	23	VMOD
27	of	of	I-PP	IN	O	26	PMOD
28	widespread	widespread	B-NP	JJ	O	30	NMOD
29	bacterial	bacterial	I-NP	JJ	O	30	NMOD
30	resistance	resistance	I-NP	NN	O	26	PMOD
31	due	due	B-PP	JJ	O	30	NMOD
32	to	to	B-PP	TO	O	31	AMOD
33	unrestricted	unrestricted	B-NP	JJ	O	34	AMOD
34	antibiotic	antibiotic	I-NP	JJ	O	35	NMOD
35	use	use	I-NP	NN	O	32	PMOD
36	.	.	O	.	O	23	P

1	The	The	B-NP	DT	O	3	NMOD
2	recurrence	recurrence	I-NP	NN	O	3	NMOD
3	rate	rate	I-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	infection	infection	B-NP	NN	O	4	PMOD
6	at	at	B-PP	IN	O	3	NMOD
7	1	1	B-NP	CD	O	8	NMOD
8	year	year	I-NP	NN	O	6	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	high	high	B-ADJP	JJ	O	9	PRD
11	,	,	O	,	O	9	P
12	as	as	B-PP	IN	O	9	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	result	result	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	recrudescence	recrudescence	B-NP	NN	O	15	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	incompletely	incompletely	B-NP	RB	O	19	AMOD
19	eradicated	eradicate	I-NP	VBN	O	20	NMOD
20	organisms	organism	I-NP	NNS	O	17	PMOD
21	rather	rather	B-PP	RB	O	22	PMOD
22	than	than	I-PP	IN	O	12	PMOD
23	reinfection	reinfection	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	9	P

